The previously described association of SMARCA2 loss with rare BAF-deficient sarcomas19,42 and/or lung sarcomatoid carcinomas41 (the latter of which represented <1% of the lung cancers profiled, Supplementary Fig. 1d) would suggest it represents a minor percentage of SMARCA4-mutant cases43,44, but nevertheless testing for SMARCA2 expression should be considered for future SMARCA2-targeted therapies. The gene discussed is SMARCA2; the disease is lung carcinoma.